372 results on '"Purpura, Thrombotic Thrombocytopenic genetics"'
Search Results
102. Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP).
- Author
-
Winters JL
- Subjects
- Complement Activation genetics, Complement System Proteins genetics, Complement System Proteins metabolism, Humans, Mutation, Plasma Exchange, Randomized Controlled Trials as Topic, Signal Transduction genetics, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic metabolism, Purpura, Thrombotic Thrombocytopenic pathology, Purpura, Thrombotic Thrombocytopenic therapy
- Abstract
Thrombotic microangiopathies (TMAs) are a diverse group of disorders that are characterized by common clinical and laboratory features. The most commonly thought-of TMA is thrombotic thrombocytopenic purpura (TTP). Because of the marked improvement in patient mortality associated with the use of therapeutic plasma exchange (TPE) in TTP, this therapy has been applied to all of the TMAs. The issue, however, is that the pathophysiology varies and in many instances may represent a disorder of the endothelium and not the blood; in some cases, the pathophysiology is unknown. The use of TPE is further obscured by a lack of strong supporting literature on its use, with most consisting of case series and case reports; controlled or randomized controlled trials are lacking. Evidence supporting the use of TPE in the treatment of TMAs (other than TTP and TMA-complement mediated) is lacking, and therefore its role is uncertain. With the greater availability of genetic testing for mutations involving complement regulatory genes and complement pathway components, there seems to be a percentage of TMA cases, other than TMA-complement mediated, in which complement pathway mutations are involved in some patients. The ability of TPE to remove abnormal complement pathway components and replace them with normal components may support its use in some patients with TMAs other than TTP and TMA-complement mediated., Competing Interests: Conflict-of-interest disclosure: The author is on the Board of Directors or an advisory committee for Eliaz Therapeutics Inc and has consulted for Regional Health Inc, Grifols International SA, and Fresenius Kabi USA., (© 2016 by The American Society of Hematology. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
103. The ADAMTS13 1239-1253 peptide is a dominant HLA-DR1-restricted CD4 + T-cell epitope.
- Author
-
Gilardin L, Delignat S, Peyron I, Ing M, Lone YC, Gangadharan B, Michard B, Kherabi Y, Sharma M, Pashov A, Latouche JB, Hamieh M, Toutirais O, Loiseau P, Galicier L, Veyradier A, Kaveri S, Maillère B, Coppo P, and Lacroix-Desmazes S
- Subjects
- ADAMTS13 Protein chemistry, Alleles, Amino Acid Sequence, Animals, Antigen-Presenting Cells immunology, Antigen-Presenting Cells metabolism, CD4-Positive T-Lymphocytes metabolism, Epitopes, T-Lymphocyte chemistry, HLA-DR1 Antigen chemistry, HLA-DR1 Antigen metabolism, Humans, Immunization, Immunodominant Epitopes chemistry, Immunoglobulin G immunology, Mice, Mice, Transgenic, Peptide Fragments chemistry, Peptide Fragments metabolism, Protein Binding immunology, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic immunology, Purpura, Thrombotic Thrombocytopenic metabolism, ADAMTS13 Protein immunology, CD4-Positive T-Lymphocytes immunology, Epitopes, T-Lymphocyte immunology, HLA-DR1 Antigen immunology, Immunodominant Epitopes immunology, Peptide Fragments immunology
- Abstract
Acquired thrombotic thrombocytopenic purpura is a rare and severe disease characterized by auto-antibodies directed against "A Disintegrin And Metalloproteinase with Thrombospondin type 1 repeats, 13
th member" (ADAMTS13), a plasma protein involved in hemostasis. Involvement of CD4+ T cells in the pathogenesis of the disease is suggested by the IgG isotype of the antibodies. However, the nature of the CD4+ T-cell epitopes remains poorly characterized. Here, we determined the HLA-DR-restricted CD4+ T-cell epitopes of ADAMTS13. Candidate T-cell epitopes were predicted in silico and binding affinities were confirmed in competitive enzyme-linked immunosorbent assays. ADAMTS13-reactive CD4+ T-cell hybridomas were generated following immunization of HLA-DR1 transgenic mice (Sure-L1 strain) and used to screen the candidate epitopes. We identified the ADAMTS131239-1253 peptide as the single immunodominant HLA-DR1-restricted CD4+ T-cell epitope. This peptide is located in the CUB2 domain of ADAMTS13. It was processed by dendritic cells, stimulated CD4+ T cells from Sure-L1 mice and was recognized by CD4+ T cells from an HLA-DR1-positive patient with acute thrombotic thrombocytopenic purpura. Interestingly, the ADAMTS131239-1253 peptide demonstrated promiscuity towards HLA-DR11 and HLA-DR15. Our work paves the way towards the characterization of the ADAMTS13-specific CD4+ T-cell response in patients with thrombotic thrombocytopenic purpura using ADAMTS131239-1253 -loaded HLA-DR tetramers., (Copyright© Ferrata Storti Foundation.)- Published
- 2017
- Full Text
- View/download PDF
104. A novel homozygous frameshift mutation in Exon 7 of the ADAMTS13 gene in a patient with congenital thrombotic thrombocytopenic purpura from India: a case report.
- Author
-
Yadav S, Shetty S, and Kulkarni B
- Subjects
- ADAMTS13 Protein immunology, ADAMTS13 Protein metabolism, Child, Preschool, Exons, Humans, India, Male, Pedigree, ADAMTS13 Protein genetics, Anemia, Hemolytic genetics, Frameshift Mutation, Homozygote, Purpura, Thrombotic Thrombocytopenic genetics
- Abstract
Background: Thrombotic thrombocytopenia purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by thrombocytopenia and microangiopathic hemolytic anemia. It is caused by deficiency of ADAMTS13 metalloprotease, which cleaves ultra-large von Willebrand factor into smaller functional units. TTP may be congenital or acquired, and the congenital form is caused by inherited mutations in the ADAMTS13 gene, leading to deficiency of protein or reduced protein activity., Case Report: We report a 5-year-old male patient who manifested with thrombocytopenia and microangiopathic hemolytic anemia at the age of 1 year., Conclusion: ADAMTS13 activity in the patient was below 5%, and ADAMTS13 antibody was absent. Subsequent genetic analysis of the ADAMTS13 gene revealed a novel homozygous mutation (i.e., frameshift insertion mutation A237GfsX153 [c.708_709insG] in Exon 7 of ADAMTS13). Both parents were heterozygous for this mutation., (© 2017 AABB.)
- Published
- 2017
- Full Text
- View/download PDF
105. Thrombotic thrombocytopenic purpura related to ADAMTS13 deficiency, and successful treatment in a chimpanzee (Pan troglodytes verus).
- Author
-
van Bolhuis H, Wolters M, de Boer M, Fijnheer R, van Zijll Langhout M, Niphuis H, and Eckmann C
- Subjects
- Animals, Ape Diseases genetics, Diagnosis, Differential, Male, Purpura, Thrombotic Thrombocytopenic drug therapy, Purpura, Thrombotic Thrombocytopenic genetics, ADAMTS13 Protein deficiency, Anticoagulants therapeutic use, Ape Diseases drug therapy, Pan troglodytes, Prednisone therapeutic use, Purpura, Thrombotic Thrombocytopenic veterinary
- Abstract
A 27-year-old male chimpanzee (Pan troglodytes verus) developed signs of thrombotic thrombocytopenic purpura (TTP). ADAMTS13 deficiency appeared to be the cause of disease. After treatment with high-dose prednisone, haematological values and clinical signs recovered. This is the first description of spontaneous TTP associated with ADAMTS13 deficiency in a non-human primate., (© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
106. Upshaw-Schulman Syndrome: Novel homozygous missense mutation.
- Author
-
Sarmiento H, Pomares IM, Manresa PM, Castaño FL, Hernandez LM, and Marco P
- Subjects
- Adult, Female, Humans, Purpura, Thrombotic Thrombocytopenic pathology, Mutation, Missense genetics, Purpura, Thrombotic Thrombocytopenic genetics
- Published
- 2017
- Full Text
- View/download PDF
107. Acquired thrombotic thrombocytopenic purpura in pregnancy: The role of placental and breast-milk mediated transfer of ADAMTS13-autoantibodies.
- Author
-
Rottenstreich A, Kalish Y, Tvito A, Hauschner H, and Arad A
- Subjects
- Adult, Animals, Female, Humans, Pregnancy, ADAMTS13 Protein genetics, Milk metabolism, Placenta metabolism, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic metabolism
- Published
- 2017
- Full Text
- View/download PDF
108. Thrombotic thrombocytopenic purpura.
- Author
-
Joly BS, Coppo P, and Veyradier A
- Subjects
- Acetylcysteine therapeutic use, Adult, Age of Onset, Antibodies, Monoclonal therapeutic use, Autoantibodies blood, Bortezomib therapeutic use, Female, Humans, Immunologic Factors therapeutic use, Male, Mutation, Plasma Exchange, Single-Domain Antibodies therapeutic use, ADAMTS13 Protein deficiency, Purpura, Thrombotic Thrombocytopenic blood, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic therapy, Sex Characteristics
- Abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia linked to disseminated microvascular platelet rich-thrombi. TTP is specifically related to a severe deficiency in ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13), the specific von Willebrand factor-cleaving protease. ADAMTS13 deficiency is most frequently acquired via ADAMTS13 autoantibodies, but rarely, it is inherited via mutations of the ADAMTS13 gene. The first acute episode of TTP usually occurs during adulthood, with a predominant anti-ADAMTS13 autoimmune etiology. In rare cases, however, TTP begins as soon as childhood, with frequent inherited forms. TTP is ∼2-fold more frequent in women, and its outcome is characterized by a relapsing tendency. Rapid recognition of TTP is crucial to initiate appropriate treatment. The first-line therapy for acute TTP is based on daily therapeutic plasma exchange supplying deficient ADAMTS13, with or without steroids. Additional immune modulators targeting ADAMTS13 autoantibodies are mainly based on steroids and the humanized anti-CD20 monoclonal antibody rituximab. In refractory or unresponsive TTP, more intensive therapies including twice-daily plasma exchange; pulses of cyclophosphamide, vincristine, or cyclosporine A; or salvage splenectomy are considered. New drugs including N -acetylcysteine, bortezomib, recombinant ADAMTS13, and caplacizumab show promise in the management of TTP. Also, long-term follow-up of patients with TTP is crucial to identify the occurrence of other autoimmune diseases, to control relapses, and to evaluate psychophysical sequelae. Further development of both patients' registries worldwide and innovative drugs is still needed to improve TTP management., (© 2017 by The American Society of Hematology.)
- Published
- 2017
- Full Text
- View/download PDF
109. Long-Term Prevention of Congenital Thrombotic Thrombocytopenic Purpura in ADAMTS13 Knockout Mice by Sleeping Beauty Transposon-Mediated Gene Therapy.
- Author
-
Verhenne S, Vandeputte N, Pareyn I, Izsvák Z, Rottensteiner H, Deckmyn H, De Meyer SF, and Vanhoorelbeke K
- Subjects
- ADAMTS13 Protein genetics, Animals, Disease Models, Animal, Feasibility Studies, Genetic Predisposition to Disease, Mice, 129 Strain, Mice, Inbred C57BL, Mice, Knockout, Phenotype, Purpura, Thrombotic Thrombocytopenic enzymology, Purpura, Thrombotic Thrombocytopenic genetics, Time Factors, von Willebrand Factor, ADAMTS13 Protein deficiency, DNA Transposable Elements, Genetic Therapy methods, Purpura, Thrombotic Thrombocytopenic prevention & control, Transposases genetics
- Abstract
Objective: Severe deficiency in the von Willebrand factor-cleaving protease ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13) because of mutations in the ADAMTS13 gene can lead to acute episodes of congenital thrombotic thrombocytopenic purpura (TTP), requiring prompt treatment. Current treatment consists of therapeutic or prophylactic infusions of fresh frozen plasma. However, lifelong treatment with plasma products is a stressful therapy for TTP patients. Here, we describe the use of the nonviral sleeping beauty (SB) transposon system as a gene therapeutic approach to realize lifelong expression of ADAMTS13 and subsequent protection against congenital TTP., Approach and Results: We demonstrated that hydrodynamic tail vein injection of the SB100X system expressing murine ADAMTS13 in Adamts13
-/- mice resulted in long-term expression of supraphysiological levels of transgene ADAMTS13 over a period of 25 weeks. Stably expressed ADAMTS13 efficiently removed the prothrombotic ultralarge von Willebrand factor multimers present in the circulation of Adamts13-/- mice. Moreover, mice stably expressing ADAMTS13 were protected against TTP. The treated mice did not develop severe thrombocytopenia or did organ damage occur when triggered with recombinant von Willebrand factor, and this up to 20 weeks after gene transfer., Conclusions: These data demonstrate the feasibility of using SB100X-mediated gene therapy to achieve sustained expression of transgene ADAMTS13 and long-term prophylaxis against TTP in Adamts13-/- mice., (© 2017 American Heart Association, Inc.)- Published
- 2017
- Full Text
- View/download PDF
110. N -acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura.
- Author
-
Tersteeg C, Roodt J, Van Rensburg WJ, Dekimpe C, Vandeputte N, Pareyn I, Vandenbulcke A, Plaimauer B, Lamprecht S, Deckmyn H, Lopez JA, De Meyer SF, and Vanhoorelbeke K
- Subjects
- ADAMTS13 Protein genetics, ADAMTS13 Protein metabolism, Animals, Disease Models, Animal, Drug Evaluation, Preclinical, Female, Gene Deletion, Male, Mice, Mice, Inbred C57BL, Papio, Purpura, Thrombotic Thrombocytopenic drug therapy, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic metabolism, von Willebrand Factor chemistry, Acetylcysteine therapeutic use, Protein Multimerization drug effects, Purpura, Thrombotic Thrombocytopenic prevention & control, von Willebrand Factor metabolism
- Abstract
Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic disorder diagnosed by thrombocytopenia and hemolytic anemia, associated with a deficiency in von Willebrand factor (VWF)-cleaving protease ADAMTS13. Current treatment is based on plasma infusion for congenital TTP, or plasma exchange, often in combination with immunosuppressive agents, for acquired TTP. These treatment methods are not always effective; therefore, new treatment methods are highly necessary. N -acetylcysteine (NAC), an FDA-approved anti-mucolytic agent, is a possible new treatment strategy for TTP, as it was demonstrated to reduce disulfide bonds in VWF, thereby decreasing VWF multimers size and hence their prothrombotic potential. We investigated whether NAC, without concurrent plasma exchange and immunosuppressive therapy, is effective in preventing and resolving TTP signs, using well-established murine and baboon models for TTP. In mice, prophylactic administration of NAC was effective in preventing severe TTP signs. This in vivo finding was supported by in vitro data demonstrating the VWF multimer-reducing properties of NAC in solution. Nonetheless, in both mice and baboons, administration of NAC was not effective in resolving preexisting TTP signs; thrombocytopenia, hemolytic anemia, and organ damage could not be reversed, as thrombus resolution was not achieved. Failure to improve clinical outcome occurred even though a reduction in VWF multimers was observed, demonstrating that NAC was efficient in reducing disulfide bonds in circulating VWF multimers. In conclusion, prophylactic administration of NAC, without concurrent plasma exchange, was effective in preventing severe TTP signs in mice, but NAC was not effective in resolving preexistent acute TTP signs in mice and baboons., (© 2017 by The American Society of Hematology.)
- Published
- 2017
- Full Text
- View/download PDF
111. The role of human leukocyte antigen DRB1-DQB1 haplotypes in the susceptibility to acquired idiopathic thrombotic thrombocytopenic purpura.
- Author
-
Sinkovits G, Szilágyi Á, Farkas P, Inotai D, Szilvási A, Tordai A, Rázsó K, Réti M, and Prohászka Z
- Subjects
- Adult, Aged, Autoantibodies blood, Female, Gene Frequency, Genotype, Histocompatibility Testing, Humans, Hungary, Male, Middle Aged, Polymorphism, Genetic, Protein Tyrosine Phosphatase, Non-Receptor Type 22 genetics, ADAMTS13 Protein immunology, Genetic Predisposition to Disease, HLA-DQ beta-Chains genetics, HLA-DRB1 Chains genetics, Purpura, Thrombotic Thrombocytopenic genetics
- Abstract
The acquired form of idiopathic thrombotic thrombocytopenic purpura (TTP) is an autoimmune disease, in which the underlying ADAMTS13-deficiency is caused by inhibitory autoantibodies against the protease. Human leukocyte antigens (HLA), responsible for antigen presentation, play an important role in the development of antibodies. The loci coding HLA DR and DQ molecules are inherited in linkage as haplotypes. The c.1858C>T polymorphism of the PTPN22 gene, which codes a protein tyrosine phosphatase important in lymphocyte activation, predisposes to a number of autoimmune diseases. We determined the HLA-DRB1-DQB1 haplotypes and the PTPN22 c.1858C>T genotypes in 75 patients with acquired idiopathic TTP and in healthy controls, in order to assess the role of these genetic factors and their interactions in the susceptibility to TTP. We found that the carrier frequencies of the DRB1
∗ 11-DQB1∗ 03 and DRB1∗ 15-DQB1∗ 06 haplotypes were higher, while those of the DRB1∗ 07-DQB1∗ 02 and DRB1∗ 13-DQB1∗ 06 haplotypes were lower in TTP patients. There was no difference in the overall frequency of the PTPN22 c.1858T allele between TTP patients and controls. In conclusion, we identified four HLA-DRB1-DQB1 haplotypes associated with an increased (DRB1∗ 11-DQB1∗ 03 and DRB1∗ 15-DQB1∗ 06) or a decreased (DRB1∗ 07-DQB1∗ 02 and DRB1∗ 13-DQB1∗ 06) susceptibility to acquired idiopathic TTP., (Copyright © 2016 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
112. TTP: One of the TMA's-How to sort it out.
- Author
-
Rock G, Clark W, Foley R, Huang S, Laroche V, Klassen J, Patriquin C, and Pavenski K
- Subjects
- Female, Humans, Male, Purpura, Thrombotic Thrombocytopenic genetics, ADAMTS13 Protein genetics, Purpura, Thrombotic Thrombocytopenic diagnosis
- Published
- 2017
- Full Text
- View/download PDF
113. Siblings with congenital thrombotic thrombocytopenic purpura.
- Author
-
Funakoshi Y, Okada M, Matsumoto M, Kokame K, and Moriuchi H
- Subjects
- Adolescent, Adult, Child, Female, Humans, Male, Purpura, Thrombotic Thrombocytopenic enzymology, Siblings, ADAMTS13 Protein genetics, Purpura, Thrombotic Thrombocytopenic congenital, Purpura, Thrombotic Thrombocytopenic genetics
- Abstract
Congenital thrombotic thrombocytopenic purpura (TTP) is a rare hereditary deficiency of ADAMTS13 (von Willebrand factor-cleaving protease) characterized by thrombocytopenia and microangiopathic hemolytic anemia. The spectrum of the clinical phenotype is wide, ranging from asymptomatic episodes of thrombocytopenia to life-threatening multiorgan failure. Reportedly, some patients develop isolated thrombocytopenia during childhood. We herein report sibling cases of congenital TTP. An 11-year-old boy with thrombocytopenia accompanied by influenza virus infection was referred to our hospital. He had a history of severe neonatal jaundice. His 15-year-old brother also had recurrent thrombocytopenia with approximately 10 episodes of recurrence since 3 years of age. Their ADAMTS13 activities were low and ADAMTS13 inhibitors were negative, and a gene analysis confirmed the diagnosis of congenital TTP. Notably, congenital TTP should be included in the differential diagnosis, and it is essential to determine the ADAMTS13 activity for pediatric patients with thrombocytopenia of unknown etiology.
- Published
- 2017
- Full Text
- View/download PDF
114. Inherited ADMATS13 deficiency: When to evoke the in the newborn?
- Author
-
Kasdallah N, Ben Salem H, Kbaier H, Ouederni M, Blibech S, and Douagi M
- Subjects
- ADAMTS13 Protein deficiency, Delayed Diagnosis, Diagnosis, Differential, Genetic Carrier Screening, Humans, Infant, Newborn, Infant, Newborn, Diseases genetics, Male, Neonatal Screening methods, Neonatal Screening standards, Purpura, Thrombotic Thrombocytopenic genetics, Tunisia, ADAMTS13 Protein genetics, Infant, Newborn, Diseases diagnosis, Purpura, Thrombotic Thrombocytopenic diagnosis
- Abstract
Inherited ADMATS13 or Upshaw-Schulman syndrome (USS) is caused by the deficiency of the Von Willebrand factor-cleaving protease. It is characterized by recurrent episodes of thrombocytopenia reversible by fresh frozen plasma (FFP) infusions, microangiopathic hemolytic anemia, and microvascular thrombosis leading to ischemic damage of multiple organs with end stage renal failure, or neurological sequelae in the absence of appropriate treatment. The typically reported features of USS in neonates are severe jaundice with hyperbilirubinemia, thrombocytopenia and /or combs negative hemolytic anemia, and an increased creatinine.We presented a clinical case of USS with unusual features, which delayed the diagnosis.USS was declared at sixth hours of life with diffuse hemorrhage related to an early neonatal infection. Analysis of the plasma, at the age of 20 months, revealed low ADAMTS13 activity in the patient (<1%).Inherited ADMATS13 deficiency manifestations may overlap with other conditions, which may delay diagnosis and lead to visceral and neurological damage. The diagnosis should be, early considered in some clinical conditions: discrepancy between the severity of a hemorrhagic syndrome and thrombocytopenia, recurrence, resistance to symptomatic treatment. The diagnosis can be suggested by the normalization of platelet count after FFP transfusions.
- Published
- 2017
115. Thrombosis and von Willebrand Factor.
- Author
-
Shahidi M
- Subjects
- ADAMTS13 Protein genetics, Blood Platelets pathology, Blood Vessels injuries, Blood Vessels metabolism, Blood Vessels pathology, Extracellular Traps metabolism, Factor VIII genetics, Factor VIII therapeutic use, Fibrinolytic Agents therapeutic use, Gene Expression Regulation, Hemostasis physiology, Humans, Plasma Exchange, Platelet Adhesiveness, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic pathology, Purpura, Thrombotic Thrombocytopenic therapy, Receptors, Collagen blood, Receptors, Collagen genetics, Signal Transduction, Tacrolimus therapeutic use, Thrombosis genetics, Thrombosis pathology, Thrombosis therapy, von Willebrand Factor genetics, ADAMTS13 Protein blood, Blood Platelets metabolism, Factor VIII metabolism, Purpura, Thrombotic Thrombocytopenic blood, Thrombosis blood, von Willebrand Factor metabolism
- Abstract
One of the key players in both hemostasis and thrombosis is von Willebrand factor (vWF), which demonstrates a duality between these two processes. Thrombus is structured by numerous elements, including endothelial cells, platelets, plasma proteins and shear stress alteration. In circulation, once a vessel wall is injured, collagen is exposed and platelets attach to the site of injury. Accordingly, vWF mediates adherence of platelets to the damaged vessel wall by binding both to the collagen and platelet receptor. A growing body of data also indicates a role for neutrophil extracellular traps (NETs) in human thrombosis as scaffolds for vWF, promoting thrombosis. VWF also mediates the protection of factor VIII, a main cofactor of the intrinsic clotting pathway. Since vWF plays a critical role in both thrombotic and bleeding events, a decreased plasma level of this factor may point to a bleeding disorder, while an elevated plasma level may predict occurrence of thrombosis. Since thrombotic events are the foremost cause of death, inhibiting the vWF activity would be a novel prophylaxis to reduce these events. Though, accumulated data have made vWF a promising focus for research on cardiovascular diseases (CVD). This chapter, however, aims to clarify the role of vWF in thrombus formation and pathogenesis of thrombosis.
- Published
- 2017
- Full Text
- View/download PDF
116. [Upshaw-Schulman syndrome. A case based on 3 genomic variants].
- Author
-
Manresa Manresa P, Sarmiento Palao H, and Hernández Mateo LM
- Subjects
- Genetic Markers, Heterozygote, Homozygote, Humans, Male, Middle Aged, Phenotype, Purpura, Thrombotic Thrombocytopenic genetics, ADAMTS13 Protein genetics, Mutation, Purpura, Thrombotic Thrombocytopenic diagnosis
- Published
- 2016
- Full Text
- View/download PDF
117. Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura.
- Author
-
Mancini I, Ricaño-Ponce I, Pappalardo E, Cairo A, Gorski MM, Casoli G, Ferrari B, Alberti M, Mikovic D, Noris M, Wijmenga C, and Peyvandi F
- Subjects
- Adult, Alleles, Autoantibodies immunology, Autoimmunity, Case-Control Studies, Chromosome Mapping, Europe, Female, Genotype, Humans, Italy, Male, Middle Aged, Polymorphism, Single Nucleotide, Principal Component Analysis, Risk Factors, Genetic Predisposition to Disease, HLA-DQ beta-Chains genetics, Purpura, Thrombotic Thrombocytopenic genetics
- Abstract
Essentials Genetic predisposition to acquired thrombotic thrombocytopenic purpura (aTTP) is mainly unknown. Genetic risk factors for aTTP were studied by Immunochip analysis and replication study. Human leukocyte antigen (HLA) variant rs6903608 conferred a 2.5-fold higher risk of developing aTTP. rs6903608 and HLA-DQB1*05:03 may explain most of the HLA association signal in aTTP. Click to hear Dr Cataland's presentation on acquired thrombotic thrombocytopenic purpura SUMMARY: Background Acquired thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy associated with the development of autoantibodies against the von Willebrand factor-cleaving protease ADAMTS-13. Similarly to what has been found for other autoimmune disorders, there is evidence of a genetic contribution, including the association of the human leukocyte antigen (HLA) class II complex with disease risk. Objective To identify novel genetic risk factors in acquired TTP. Patients/Methods We undertook a case-control genetic association study in 190 European-origin TTP patients and 1255 Italian healthy controls by using the Illumina Immunochip. Replication analysis in 88 Italian cases and 456 controls was performed with single-nucleotide polymorphism (SNP) TaqMan assays. Results and conclusion We identified one common variant (rs6903608) located within the HLA class II locus that was independently associated with acquired TTP at genome-wide significance and conferred a 2.6-fold increased risk of developing a TTP episode (95% confidence interval [CI] 2.02-3.27, P = 1.64 × 10
-14 ). We also found five non-HLA variants mapping to chromosomes 2, 6, 8 and X that were suggestively associated with the disease: rs9490550, rs115265285, rs5927472, rs7823314, and rs1334768 (nominal P-values ranging from 1.59 × 10-5 to 7.60 × 10-5 ). Replication analysis confirmed the association of HLA variant rs6903608 with acquired TTP (pooled P = 3.95 × 10-19 ). Imputation of classic HLA genes followed by stepwise conditional analysis revealed that the combination of rs6903608 and HLA-DQB1*05:03 may explain most of the HLA association signal in acquired TTP. Our results refined the association of the HLA class II locus with acquired TTP, confirming its importance in the etiology of this autoimmune disease., (© 2016 International Society on Thrombosis and Haemostasis.)- Published
- 2016
- Full Text
- View/download PDF
118. Severe Hemolysis and Pulmonary Hypertension in a Neonate With Upshaw-Schulman Syndrome.
- Author
-
Tsujii N, Shiraishi I, Kokame K, Shima M, Fujimura Y, Takahashi Y, and Matsumoto M
- Subjects
- Echocardiography, Female, Humans, Infant, Newborn, Mutation, Purpura, Thrombotic Thrombocytopenic congenital, Purpura, Thrombotic Thrombocytopenic genetics, ADAMTS13 Protein genetics, Hemolysis, Hypertension, Pulmonary etiology, Purpura, Thrombotic Thrombocytopenic complications
- Abstract
Pulmonary involvement is extremely rare in thrombotic thrombocytopenic purpura. In this report, we present a girl patient with congenital thrombotic thrombocytopenic purpura, known as Upshaw-Schulman syndrome (USS), complicated with severe hemolysis and pulmonary hypertension (PH). The assay results of a disintegrin-like and metalloprotease with thrombospondin type 1 motifs 13 (ADAMTS13) activity measured by FRETS-VWF73 and ADAMTS13-act-ELISA were different. Hyperbilirubinemia (total bilirubin, 25.3 mg/dL) interfered strongly with the FRETS-VWF73 assay. Plasma levels of ADAMTS13 activity by act-ELISA were <0.5% of normal. The diagnosis of USS was confirmed by ADAMTS13 gene analysis, which showed compound heterozygous mutations of p.G139Vfs*17 and p.I673F. The p.G139Vfs*17 mutation was previously unreported, and its effect in splicing was confirmed by reverse transcription polymerase chain reaction. The patient received oxygen therapy for PH and exchange blood transfusion for severe hemolysis. The PH resolved without specific treatment. Based on these findings, the PH may have been caused by free hemoglobin that scavenged nitrogen oxide or platelet thrombi in the lungs caused by ADAMTS13 deficiency. Thus, severe PH can occur in neonatal patients with USS, and severe hemolysis might result in overestimation of ADAMTS 13 activity. Both possibilities are important for the diagnosis and management of USS., (Copyright © 2016 by the American Academy of Pediatrics.)
- Published
- 2016
- Full Text
- View/download PDF
119. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
- Author
-
Joly BS, Stepanian A, Leblanc T, Hajage D, Chambost H, Harambat J, Fouyssac F, Guigonis V, Leverger G, Ulinski T, Kwon T, Loirat C, Coppo P, and Veyradier A
- Subjects
- ADAMTS13 Protein blood, ADAMTS13 Protein genetics, Adolescent, Age Factors, Age of Onset, Child, Child, Preschool, Cohort Studies, Female, France, Genetic Predisposition to Disease, Humans, Infant, Male, Registries, Rituximab therapeutic use, ADAMTS13 Protein deficiency, Purpura, Thrombotic Thrombocytopenic blood, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic therapy
- Abstract
Background: Thrombotic thrombocytopenic purpura is a rare thrombotic microangiopathy, related to a severe ADAMTS13 deficiency (a disintegrin and metalloprotease with thromboSpondin type 1 repeats, member 13; activity <10% of normal). Childhood-onset thrombotic thrombocytopenic purpura is very rare and initially often misdiagnosed, especially when ADAMTS13 deficiency is acquired (ie, not linked to inherited mutations of the ADAMTS13 gene). We aimed to investigate initial presentation, management, and outcome of acquired thrombotic thrombocytopenic purpura in children., Methods: Between Jan 1, 2000, and Dec 31, 2015, we studied a cohort of patients with child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura included in the French national registry for thrombotic microangiopathies at presentation and during follow up. The inclusion criteria were: first episode before age 18 years; ADAMTS13 activity less than 10% of normal at presentation; positive anti-ADAMTS13 autoantibodies during an episode, or a recovery of ADAMTS13 activity in remission, or both. ADAMTS13 activity and anti-ADAMTS13 autoantibodies were investigated by a central laboratory, and medical records were extensively reviewed to collect clinical and biological features with a standardised form. This study is registered with ClinicalTrials.gov, number NCT00426686., Findings: We enrolled 973 patients with childhood-onset thrombotic microangiopathy, of whom 74 had a severe ADAMTS13 deficiency (activity <10%) at presentation. 24 patients had an inherited thrombotic thrombocytopenic purpura also known as Upshaw-Schulman syndrome and five did not have follow-up data available, thus 45 children had acquired thrombotic thrombocytopenic purpura and were included in our database at presentation. 25 (56%) patients had idiopathic disease and 20 (44%) had miscellaneous associated clinical conditions. At diagnosis, median age was 13 years (IQR 7-16, range 4 months-17 years), with a sex ratio of 2·5 girls to 1 boy. Anti-ADAMTS13 autoantibodies were positive in 37 (82%) of 45 patients (24 [96%] of 25 idiopathic cases and 13 [65%] of 20 non-idiopathic cases). 39 (87%) of 45 patients were given plasma therapy and 21 (47%) received additional rituximab. Four (9%) children died after the first thrombotic thrombocytopenic purpura episode. Long-term follow up of the 41 survivors showed that ten (24%) patients relapsed and systemic lupus erythematosus occurred in two (5%) patients. Preemptive rituximab was used in seven (17%) of 41 patients with acquired thrombotic thrombocytopenic purpura., Interpretation: Our study shows that child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura have specific clinical, biological and therapeutic features. Long-term follow-up is crucial to prevent relapses of the disease, to identify the occurrence of autoimmune disorders, and to evaluate consequences on social life. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura is a crucial diagnosis in the field of paediatric haematologic cytopenias because it is a life-threatening disease requiring a specific management., Funding: Assistance Publique-Hôpitaux de Paris, France., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
120. Degradation of two novel congenital TTP ADAMTS13 mutants by the cell proteasome prevents ADAMTS13 secretion.
- Author
-
Underwood M, Peyvandi F, Garagiola I, Machin S, and Mackie I
- Subjects
- ADAMTS13 Protein metabolism, HEK293 Cells, Humans, Proteasome Endopeptidase Complex metabolism, Proteolysis, Purpura, Thrombotic Thrombocytopenic metabolism, ADAMTS13 Protein genetics, Point Mutation, Purpura, Thrombotic Thrombocytopenic genetics
- Abstract
Introduction: Over 150 mutations have been identified in the ADAMTS13 gene in patients with congenital thrombotic thrombocytopenic purpura (TTP). The majority of these (86%), lead to reduced (<50%) secretion of mutant recombinant ADAMTS13. The mechanism by which this occurs has not been investigated in vitro. Two novel ADAMTS13 mutations (p.I143T and p.Y570C) identified in two congenital adolescence onset TTP patients were studied, to investigate their effects on ADAMTS13 secretion and subcellular localisation., Materials and Methods: HEK293T cells were transiently transfected with wild type or mutant ADAMTS13 cDNA. Immunofluorescence and confocal microscopy were used to study localisation within the endoplasmic reticulum (ER) and Golgi. The cell proteasome and lysosomes were inhibited in cells stably expressing ADAMTS13 to investigate degradation of ADAMTS13 by either organelle., Results: Both mutations severely impaired secretion and both mutants localised within the ER and Golgi. Proteasome inhibition led to the intracellular accumulation of both mutants, suggesting proteasome degradation. Lysosome inhibition on the other hand did not lead to increased intracellular accumulation of the mutants., Conclusions: Proteasome degradation of these ADAMTS13 mutants contributed to their reduced secretion., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
121. Upshaw-Schulman syndrome and pregnancy: successful management with plasma infusions.
- Author
-
Gangaraju R and Rodgers GM
- Subjects
- ADAMTS13 Protein deficiency, ADAMTS13 Protein genetics, Female, Humans, Pregnancy, Pregnancy Complications genetics, Purpura, Thrombotic Thrombocytopenic congenital, Purpura, Thrombotic Thrombocytopenic genetics, Remission Induction, Young Adult, Plasma, Pregnancy Complications therapy, Purpura, Thrombotic Thrombocytopenic therapy
- Published
- 2016
- Full Text
- View/download PDF
122. Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors.
- Author
-
Martino S, Jamme M, Deligny C, Busson M, Loiseau P, Azoulay E, Galicier L, Pène F, Provôt F, Dossier A, Saheb S, Veyradier A, and Coppo P
- Subjects
- Adult, Alleles, Female, Gene Frequency, HLA-DQ beta-Chains genetics, HLA-DRB1 Chains genetics, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Purpura, Thrombotic Thrombocytopenic mortality, Registries, Risk Factors, Treatment Outcome, White People genetics, Black or African American genetics, Black People genetics, Purpura, Thrombotic Thrombocytopenic ethnology, Purpura, Thrombotic Thrombocytopenic genetics
- Abstract
Black people are at increased risk of thrombotic thrombocytopenic purpura (TTP). Whether clinical presentation of TTP in Black patients has specific features is unknown. We assessed here differences in TTP presentation and outcome between Black and White patients. Clinical presentation was comparable between both ethnic groups. However, prognosis differed with a lower death rate in Black patients than in White patients (2.7% versus 11.6%, respectively, P = .04). Ethnicity, increasing age and neurologic involvement were retained as risk factors for death in a multivariable model (P < .05 all). Sixty-day overall survival estimated by the Kaplan-Meier curves and compared with the Log-Rank test confirmed that Black patients had a better survival than White patients (P = .03). Salvage therapies were similarly performed between both groups, suggesting that disease severity was comparable. The comparison of HLA-DRB1*11, -DRB1*04 and -DQB1*03 allele frequencies between Black patients and healthy Black individuals revealed no significant difference. However, the protective allele against TTP, HLA-DRB1*04, was dramatically decreased in Black individuals in comparison with White individuals. Black people with TTP may have a better survival than White patients despite a comparable disease severity. A low natural frequency of HLA-DRB1*04 in Black ethnicity may account for the greater risk of TTP in this population.
- Published
- 2016
- Full Text
- View/download PDF
123. Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy.
- Author
-
Epperla N, Hemauer K, Friedman KD, George JN, and Foy P
- Subjects
- Biomarkers, Combined Modality Therapy, DNA Mutational Analysis, Disease Management, Enzyme Activation, Female, Humans, Phenotype, Platelet Count, Pregnancy, Purpura, Thrombotic Thrombocytopenic blood, Purpura, Thrombotic Thrombocytopenic therapy, Treatment Outcome, Young Adult, ADAMTS13 Protein genetics, Mutation, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic genetics
- Published
- 2016
- Full Text
- View/download PDF
124. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
- Author
-
Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P, Poullin P, de Maistre E, Provôt F, Delmas Y, Perez P, Benhamou Y, Stepanian A, Coppo P, and Veyradier A
- Subjects
- Adult, Autoantibodies blood, Autoimmune Diseases complications, Autoimmune Diseases etiology, Clopidogrel, Cohort Studies, Cross-Sectional Studies, Digestive System Diseases complications, Female, Fever complications, France epidemiology, Genotype, HIV Infections complications, Humans, Infections complications, Male, Middle Aged, Neoplasms complications, Nervous System Diseases complications, Pregnancy, Pregnancy Complications physiopathology, Prevalence, Purpura, Thrombocytopenic, Idiopathic complications, Purpura, Thrombotic Thrombocytopenic complications, Registries, Risk Factors, Sex Factors, Ticlopidine adverse effects, Ticlopidine analogs & derivatives, Transplantation adverse effects, ADAMTS13 Protein deficiency, ADAMTS13 Protein genetics, ADAMTS13 Protein immunology, Mutation genetics, Purpura, Thrombocytopenic, Idiopathic epidemiology, Purpura, Thrombocytopenic, Idiopathic genetics, Purpura, Thrombocytopenic, Idiopathic physiopathology, Purpura, Thrombotic Thrombocytopenic epidemiology, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic physiopathology
- Abstract
Background: Thrombotic thrombocytopenic purpura is a thrombotic microangiopathy related to a severe deficiency of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13; activity <10%). We aimed to investigate the association between mechanisms for ADAMTS13 deficiency and the epidemiology and pathophysiology of thrombotic thrombocytopenic purpura at initial presentation., Methods: Between Jan 1, 1999, and Dec 31, 2013, we did a cross-sectional analysis of the French national registry for thrombotic microangiopathy to identify all patients with adult-onset thrombotic microangiopathy (first episode after age 18 years) who had severe ADAMTS13 deficiency at presentation. ADAMTS13 activity, anti-ADAMTS13 IgG, and ADAMTS13 gene mutations were investigated by a central laboratory. We collected patients' clinical data for correlation with their ADAMTS13 phenotype and genotype. We used logistic regression analysis to identify variables significantly associated with idiopathic thrombotic thrombocytopenic purpura, as measured by estimated odds ratios (ORs) and 95% CIs. This study is registered with ClinicalTrials.gov, number NCT00426686., Findings: We enrolled 939 patients with adult-onset thrombotic thrombocytopenic purpura, of whom 772 (82%) patients had available data and samples at presentation and comprised the cohort of interest. The prevalence of thrombotic thrombocytopenic purpura in France was 13 cases per million people. At presentation, 378 (49%) patients had idiopathic thrombotic thrombocytopenic purpura, whereas 394 (51%) patients had disease associated with miscellaneous clinical situations (infections, autoimmunity, pregnancy, cancer, organ transplantation, and drugs). Pathophysiologically, three distinct forms of thrombotic thrombocytopenic purpura were observed: 585 (75%) patients had autoimmune disease with anti-ADAMTS13 IgG, 166 (22%) patients had acquired disease of unknown cause and 21 (3%) patients had inherited disease (Upshaw-Schulman syndrome) with mutations of the ADAMTS13 gene. Idiopathic thrombotic thrombocytopenic purpura were mainly autoimmune (345 [91%] cases), whereas non-idiopathic diseases were heterogeneous, including a high rate of unexplained mechanisms for ADAMTS13 deficiency (133 [34%] cases). Obstetrical thrombotic thrombocytopenic purpura cases (n=62) were specifically remarkable because of the high rate of patients with Upshaw-Schulman syndrome (21 [34%] patients)., Interpretation: Our study shows that thrombotic thrombocytopenic purpura is a heterogeneous syndrome, and that features of the disease at presentation are strongly associated with the mechanisms of ADAMTS13 deficiency. In addition to mechanistic insight, our findings could have implications for the initial therapeutic management of patients with this disorder., Funding: Assistance Publique-Hôpitaux de Paris., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
125. Congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) caused by novel ADAMTS13 mutations.
- Author
-
Kim HY, Lee KO, Yoo KH, Kim SH, Oh D, and Kim HJ
- Subjects
- ADAMTS13 Protein, Child, Female, Humans, Infant, Male, Middle Aged, Purpura, Thrombotic Thrombocytopenic enzymology, ADAM Proteins genetics, Mutation, Purpura, Thrombotic Thrombocytopenic genetics
- Published
- 2016
- Full Text
- View/download PDF
126. Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency.
- Author
-
Fan X, Kremer Hovinga JA, Shirotani-Ikejima H, Eura Y, Hirai H, Honda S, Kokame K, Taleghani MM, von Krogh AS, Yoshida Y, Fujimura Y, Lämmle B, and Miyata T
- Subjects
- ADAMTS13 Protein genetics, Adult, Atypical Hemolytic Uremic Syndrome genetics, Female, Genetic Predisposition to Disease, Humans, Male, Middle Aged, Complement C3 genetics, Genetic Association Studies, Mutation, Missense, Purpura, Thrombotic Thrombocytopenic congenital, Purpura, Thrombotic Thrombocytopenic genetics, Renal Insufficiency etiology, Renal Insufficiency genetics
- Abstract
The congenital form of thrombotic thrombocytopenic purpura (TTP) is caused by genetic mutations in ADAMTS13. Some, but not all, congenital TTP patients manifest renal insufficiency in addition to microangiopathic hemolysis and thrombocytopenia. We included 32 congenital TTP patients in the present study, which was designed to assess whether congenital TTP patients with renal insufficiency have predisposing mutations in complement regulatory genes, as found in many patients with atypical hemolytic uremic syndrome (aHUS). In 13 patients with severe renal insufficiency, six candidate complement or complement regulatory genes were sequenced and 11 missense mutations were identified. One of these missense mutations, C3:p.K155Q mutation, is a rare mutation located in the macroglobulin-like 2 domain of C3, where other mutations predisposing for aHUS cluster. Several of the common missense mutations identified in our study have been reported to increase disease-risk for aHUS, but were not more common in patients with as compared to those without renal insufficiency. Taken together, our results show that the majority of the congenital TTP patients with renal insufficiency studied do not carry rare genetic mutations in complement or complement regulatory genes.
- Published
- 2016
- Full Text
- View/download PDF
127. Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13.
- Author
-
Tersteeg C, Fijnheer R, Pasterkamp G, de Groot PG, Vanhoorelbeke K, de Maat S, and Maas C
- Subjects
- ADAM Proteins genetics, ADAMTS13 Protein, Animals, Humans, Metalloendopeptidases genetics, Metalloendopeptidases metabolism, Mice, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic pathology, von Willebrand Factor genetics, ADAM Proteins metabolism, Purpura, Thrombotic Thrombocytopenic metabolism, von Willebrand Factor metabolism
- Abstract
Von Willebrand factor (VWF) is one of the most important proteins of the hemostatic system. Its multimeric state is essential for its natural function to guide platelets to sites of injury. ADAMTS13 is the key protease that regulates the multimeric state of VWF. Without ADAMTS13, VWF multimers can grow to pathologically large sizes. This is a risk factor for the life-threatening condition thrombotic thrombocytopenic purpura (TTP). In this condition, VWF-rich thrombi occlude the microvasculature of various tissues. Intriguingly, a complete ADAMTS13 deficiency does not cause continuous TTP, either in patients or genetically targeted mice. Instead, TTP occurs in episodes of disease, separated by extended periods of remission. This indicates that regulating factors beyond ADAMTS13 are likely involved in this pathologic cascade of events. This raises the question of what really happens when ADAMTS13 is (temporarily) unavailable. In this review, we explore the possible role of complementary mechanisms that are capable of modifying the thrombogenic potential of VWF., (Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.)
- Published
- 2016
- Full Text
- View/download PDF
128. Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes.
- Author
-
Peyvandi F, Rossio R, Ferrari B, Lotta LA, Pontiggia S, Ghiringhelli Borsa N, Pizzuti M, Donadelli R, Piras R, Cugno M, and Noris M
- Subjects
- ADAMTS13 Protein blood, Atypical Hemolytic Uremic Syndrome blood, Atypical Hemolytic Uremic Syndrome diagnosis, Atypical Hemolytic Uremic Syndrome immunology, Biomarkers blood, Carboxypeptidase B2 blood, DNA Mutational Analysis, Female, Genetic Predisposition to Disease, HEK293 Cells, Heterozygote, Humans, Middle Aged, Phenotype, Purpura, Thrombotic Thrombocytopenic blood, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic immunology, Transfection, von Willebrand Factor metabolism, Atypical Hemolytic Uremic Syndrome genetics, Complement Factor I genetics, Mutation, Purpura, Thrombotic Thrombocytopenic genetics, Thrombomodulin genetics
- Abstract
Unlabelled: ESSENTIALS: The differential diagnosis among thrombotic microangiopathies (TMAs) is challenging. We studied a case of TMA with neurologic symptoms, no renal impairment and normal ADAMTS-13 levels. Two novel mutations in complement factor I and thrombomodulin genes were identified. Complement-regulator genes can be involved in TMAs with normal ADAMTS-13 regardless of renal damage., Background: Thrombotic microangiopathies (TMAs) often represent a challenge for clinicians, because clinical, laboratory, and even genetic features are not always sufficient to distinguish among different TMAs., Objectives: The aim of this study was to investigate the pathogenetic mechanisms underlying an acute case of TMA with features of both thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS)., Patients/methods: We report the case of a 49-year-old woman who developed an acute TMA with neurologic involvement and no renal impairment. ADAMTS-13, von Willebrand factor, and complement-system biochemical characterization was performed on acute phase samples. Exome sequencing and direct Sanger sequencing of previously aHUS-associated genes were performed. The functional consequences of the thrombomodulin (THBD) mutation were investigated by in vitro expression studies., Results: Despite a clinical diagnosis of TTP, the patient had normal ADAMTS-13 levels and increased VWF antigen levels with ultra-large von Willebrand factor multimers. C3, C4, and complement factors H and I (CFI) were normal. Molecular analysis confirmed two novel heterozygous mutations in CFI (c.805G>A, p.G269S) and THBD (c.1103C>T, p.P368L), and in vitro expression studies showed a reduction in the generation of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) caused by mutated THBD. This proinflammatory condition, associated with the p.G269S mutation in CFI, probably leads to a complement-mediated endothelial activation, with a relevant prothrombotic potential in case of transient environmental triggers., Conclusions: This study identified the first case of acute TMA without renal involvement but with neurological damage carrying two novel mutations in complement-regulator genes, highlighting the possible role of the complement system as a common pathogenetic mechanism in TMAs., (© 2015 International Society on Thrombosis and Haemostasis.)
- Published
- 2016
- Full Text
- View/download PDF
129. High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence.
- Author
-
von Krogh AS, Quist-Paulsen P, Waage A, Langseth ØO, Thorstensen K, Brudevold R, Tjønnfjord GE, Largiadèr CR, Lämmle B, and Kremer Hovinga JA
- Subjects
- Adolescent, Adult, Aged, Alleles, Child, Child, Preschool, Cross-Sectional Studies, Family Health, Female, Gene Frequency, Geography, Homozygote, Humans, Infant, Infant, Newborn, Male, Middle Aged, Mutation, Norway epidemiology, Prevalence, Purpura, Thrombotic Thrombocytopenic genetics, Young Adult, ADAMTS13 Protein genetics, Purpura, Thrombotic Thrombocytopenic epidemiology
- Abstract
Unlabelled: Essentials The population prevalence of hereditary thrombotic thrombocytopenic purpura (TTP) is unknown. We studied the prevalence of hereditary TTP and population frequencies of two ADAMTS-13 mutations. A high frequency of hereditary TTP related to ADAMTS-13 mutation c.4143_4144dupA was found. Vicinity of ABO blood group and ADAMTS-13 loci may facilitate screening of ADAMTS-13 mutations., Summary: Background Hereditary thrombotic thrombocytopenic purpura (TTP) caused by ADAMTS-13 mutations is a rare, but serious condition. The prevalence is unknown, but it seems to be high in Norway. Objectives To identify all patients with hereditary TTP in central Norway and to investigate the prevalence of hereditary TTP and the population frequencies of two common ADAMTS-13 mutations. Patients/Methods Patients were identified in a cross-sectional study within the Central Norway Health Region by means of three different search strategies. Frequencies of ADAMTS-13 mutations, c.4143_4144dupA and c.3178 C>T (p.R1060W), were investigated in a population-based cohort (500 alleles) and in healthy blood donors (2104 alleles) by taking advantage of the close neighborhood of the ADAMTS-13 and ABO blood group gene loci. The observed prevalence of hereditary TTP was compared with the rates of ADAMTS-13 mutation carriers in different geographical regions. Results We identified 11 families with hereditary TTP in central Norway during the 10-year study period. The prevalence of hereditary TTP in central Norway was 16.7 × 10(-6) persons. The most prevalent mutation was c.4143_4144dupA, accounting for two-thirds of disease causing alleles among patients and having an allelic frequency of 0.33% in the central, 0.10% in the western, and 0.04% in the southeastern Norwegian population. The allelic frequency of c.3178 C>T (p.R1060W) in the population was even higher (0.3-1%), but this mutation was infrequent among patients, with no homozygous cases. Conclusions We found a high prevalence of hereditary TTP in central Norway and an apparently different penetrance of ADAMTS-13 mutations., (© 2015 International Society on Thrombosis and Haemostasis.)
- Published
- 2016
- Full Text
- View/download PDF
130. The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical and in silico study.
- Author
-
Lancellotti S, Peyvandi F, Pagliari MT, Cairo A, Abdel-Azeim S, Chermak E, Lazzareschi I, Mastrangelo S, Cavallo L, Oliva R, and De Cristofaro R
- Subjects
- ADAM Proteins chemistry, ADAM Proteins metabolism, ADAMTS13 Protein, Adolescent, Amino Acid Sequence, Catalytic Domain, Consanguinity, DNA Mutational Analysis, Female, Genetic Markers, Genetic Predisposition to Disease, HEK293 Cells, Heredity, Humans, Male, Middle Aged, Molecular Dynamics Simulation, Molecular Sequence Data, Pedigree, Phenotype, Protein Conformation, Purpura, Thrombotic Thrombocytopenic blood, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic enzymology, Structure-Activity Relationship, Transfection, Young Adult, von Willebrand Factor metabolism, ADAM Proteins genetics, Mutation, Purpura, Thrombotic Thrombocytopenic genetics
- Abstract
Congenital thrombotic thrombocytopenic purpura (TTP) is a rare form of thrombotic microangiopathy, inherited with autosomal recessive mode as a dysfunction or severe deficiency of ADAMTS-13 (A Disintegrin And Metalloprotease with ThromboSpondin 1 repeats Nr. 13), caused by mutations in the ADAMTS-13 gene. About 100 mutations of the ADAMTS-13 gene were identified so far, although only a few characterised by in vitro expression studies. A new Asp to Gly homozygous mutation at position 173 of ADAMTS-13 sequence was identified in a family of Romanian origin, with some members affected by clinical signs of TTP. In two male sons, this mutation caused a severe (< 3%) deficiency of ADAMTS-13 activity and antigen level, associated with periodic thrombocytopenia, haemolytic anaemia and mild mental confusion. Both parents, who are cousins, showed the same mutation in heterozygous form. Expression studies of the mutant ADAMTS-13, performed in HEK293 cells, showed a severe decrease of the enzyme's activity and secretion, although the protease was detected inside the cells. Molecular dynamics found that in the D173G mutant the interface area between the metalloprotease domain and the disintegrin-like domain significantly decreases during the simulations, while the proline-rich 20 residues linker region (LR, 285-304) between them undergoes extensive conformational changes. Inter-domain contacts are also significantly less conserved in the mutant compared to the wild-type. Both a decrease of the inter-domain contacts along with a substantial conformational rearrangement of LR interfere with the proper maturation and folding of the mutant ADAMTS-13, thus impairing its secretion.
- Published
- 2016
- Full Text
- View/download PDF
131. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.
- Author
-
Phillips EH, Westwood JP, Brocklebank V, Wong EK, Tellez JO, Marchbank KJ, McGuckin S, Gale DP, Connolly J, Goodship TH, Kavanagh D, and Scully MA
- Subjects
- Acute Disease, Adolescent, Adult, Aged, Atypical Hemolytic Uremic Syndrome genetics, Child, Preschool, DNA Mutational Analysis, Female, Humans, Incidence, Infant, Kidney Function Tests, Male, Membrane Cofactor Protein genetics, Middle Aged, Mutation, Phenotype, Platelet Count, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic genetics, Retrospective Studies, Young Adult, ADAMTS13 Protein genetics, ADAMTS13 Protein metabolism, Complement C3 genetics, Complement Factor B genetics, Thrombotic Microangiopathies diagnosis, Thrombotic Microangiopathies genetics
- Abstract
Unlabelled: ESSENTIALS: Molecular diagnostics has improved the differentiation of acute thrombotic microangiopathys (TMAs). Atypical hemolytic uremic syndrome may have features mimicking thrombotic thrombocytopenic purpura. We identified novel complement mutations and a high incidence of CD46, with favorable long term outcomes. Complement mutation analysis in TMA where the diagnosis is unclear and ADAMTS-13 activity is >10%., Background: Differentiation of acute thrombotic microangiopathy (TMA) at presentation has historically been dependent on clinical parameters. Confirmation of thrombotic thrombocytopenic purpura (TTP) is increasingly reliant on demonstrating deficient ADAMTS-13 activity. The identification of alternative complement pathway abnormalities in atypical hemolytic uremic syndrome (aHUS), along with the proven efficacy of terminal complement inhibitors in treatment, has increased the need for rapid differentiation of TTP from aHUS., Objectives: We describe the clinical phenotype and nature of complement mutations in a cohort of aHUS patients referred as acute TMAs., Patients/methods: Fourteen consecutive aHUS patients were screened for mutations in C3, CD46, CFH, CFI, and CFB, as well as factor H (FH) antibodies. All aHUS patients had ADAMTS-13 activity > 10%., Results: Of 14 aHUS patients, 11 (79%) had platelet counts < 30 × 10(9) /L during the acute phase. Median presenting creatinine level was 295 μmol L(-1) , while five (36%) of 14 presented with a serum creatinine level < 200 μmol L(-1) . Alternative complement pathway mutations were detected in 9 (64%) of 14 patients, including CD46 mutations in five (36%) of 14 patients. Patients were identified with novel mutations in CFB and C3 that have not been previously reported., Conclusions: We demonstrate that diagnostic differentiation based on platelet count and renal function is insufficient to predict an underlying complement mutation in some aHUS cases. Specifically, we demonstrate a high frequency of functionally significant CD46 mutations which may mimic TTP. ADAMTS-13 activity > 10% in a patient with a TMA should necessitate genetic screening for complement abnormalities., (© 2015 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.)
- Published
- 2016
- Full Text
- View/download PDF
132. Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab.
- Author
-
Pecoraro C, Ferretti AV, Rurali E, Galbusera M, Noris M, and Remuzzi G
- Subjects
- ADAM Proteins genetics, ADAMTS13 Protein, Child, Humans, Male, Purpura, Thrombotic Thrombocytopenic genetics, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic drug therapy
- Abstract
A 12-year-old boy was hospitalized for hemolytic anemia, thrombocytopenia, acute kidney injury, and generalized seizures. The childhood onset, severely decreased kidney function, absence of prodromal diarrhea, negative test results for Shiga-like toxin-producing Escherichia coli, elevated plasma levels of the terminal complement complex sC5b-9, and ex vivo testing in endothelial cells showing serum-induced complement activation were all consistent with a diagnosis of complement-mediated atypical hemolytic uremic syndrome. Before plasma ADAMTS13 (von Willebrand factor protease) activity results were available, the patient was treated with the anti-C5 monoclonal antibody eculizumab, and treatment was followed by prompt disease remission. However, results of ADAMT13 activity level tests and gene screening revealed a severe deficiency associated with 2 heterozygous mutations in the ADAMTS13 gene, fully consistent with a diagnosis of congenital thrombotic thrombocytopenic purpura. Screening for atypical hemolytic uremic syndrome-associated genes failed to show a mutation and an assay for plasma anti-factor H antibodies gave negative results both before and after eculizumab treatment initiation. The patient's clinical evolution suggests that complement activation plays a role in the pathogenesis of thrombotic thrombocytopenic purpura and provides unexpected new insights into the treatment of this life-threatening disease., (Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
133. ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.
- Author
-
Rurali E, Banterla F, Donadelli R, Bresin E, Galbusera M, Gastoldi S, Peyvandi F, Underwood M, Remuzzi G, and Noris M
- Subjects
- ADAM Proteins genetics, ADAMTS13 Protein, Adolescent, Adult, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Mutation, Purpura, Thrombotic Thrombocytopenic complications, Purpura, Thrombotic Thrombocytopenic genetics, Renal Insufficiency complications, Young Adult, ADAM Proteins metabolism, ADAM Proteins physiology, Purpura, Thrombotic Thrombocytopenic blood
- Abstract
Background and Objectives: Acute renal impairment is observed in 11%-23% of patients with congenital thrombotic thrombocytopenic purpura (TTP) and deficiency of a disintegrin and metalloprotease with thrombospondin motifs 13 (ADAMTS13, a metalloprotease that cleaves von Willebrand factor [VWF] multimers), a substantial percentage of whom develop CKD during follow-up., Design, Setting, Participants, & Measurements: Here we investigated whether, in 18 patients with congenital recruited from 1996 to 2013 who fulfilled inclusion criteria, acute renal involvement occurred during bouts segregated with lower secretion and activity levels of ADAMTS13 mutants. We performed expression studies and a sensitive recombinant VWF (rVWF) A1-A2-A3 cleavage test (detection limit, 0.78% of normal ADAMTS13 activity)., Results: A higher risk of acute renal impairment during bouts was observed in patients with childhood (<18 years) onset (odds ratio [OR], 24.6 [95% confidence interval (CI), 1.11 to 542.44]) or a relapsing (≥1 episode per year) disease (OR, 54.6 [95% CI, 2.25 to 1326.28]) than in patients with adulthood onset or long-lasting remission, respectively. Whatever the age at onset, patients with acute renal impairment had mutations different from those in patients without renal involvement. Moreover, mutations in patients with acute renal impairment compared with those in patients without renal involvement caused lower in vitro rADAMTS13 secretion (1.33% versus 12.5%; P<0.001) and residual activity (0.11% versus 3.47%; P=0.003). rADAMTS13 secretion ≤3.75% and residual activity ≤0.4% best discriminated patients with renal impairment (receiver-operating characteristic curve sensitivity, 100% and 100%; specificity, 100% and 83.3%, respectively; logistic regression OR, 325 [95% CI, 6 to 18339] and 91.7 [95% CI, 3.2 to 2623.5], respectively). All mutations found in patients with childhood onset or relapsing disease were associated with acute renal impairment during bouts, confirming the link between acute renal impairment and early onset or a relapsing course. ADAMTS13 activity levels in vivo, measured in patients' serum by rVWF A1-A2-A3 cleavage test, correlated with in vitro rADAMTS13 mutant activity (r=0.95; P<0.001)., Conclusions: In congenital TTP, renal impairment and relapsing disease might be predicted by measurements of in vitro rADAMTS13 secretion and activity levels and in vivo serum ADAMTS13 activity., (Copyright © 2015 by the American Society of Nephrology.)
- Published
- 2015
- Full Text
- View/download PDF
134. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
- Author
-
Kato S and Fujimura Y
- Subjects
- ADAM Proteins deficiency, ADAM Proteins immunology, ADAMTS13 Protein, Autoantibodies blood, Biomarkers blood, Diagnosis, Differential, Humans, Immunoglobulin G blood, Mutation, Plasma, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic therapy, von Willebrand Factor metabolism, ADAM Proteins blood, ADAM Proteins genetics, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic etiology
- Abstract
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder classified with a type of thrombotic microangiopathy (TMA). TTP is caused by a deficiency of von Willebrand factor-cleaving protease called ADAMTS13 (a disintegrin-like and metalloprotease with a thrombospondin type1 motif 13). Low ADAMTS13 levels result in increased ultra-large von Willebrand factor multimers (UL-VWFM), which induce platelet adhesion and thrombosis. Congenital TTP (Upshaw-Schulman syndrome: USS) is an inherited disorder of ADAMTS13, and the other more commonly is an acquired TTP caused by autoantibodies against ADAMTS13. This article reviews the progress of ADAMTS13 activity measurement and the resulting changes in the diagnosis and treatment of TTP.
- Published
- 2015
135. Congenital late onset thrombotic thrombocytopenic purpura: a diagnostic challenge.
- Author
-
Enjeti AK, Chapman K, Taylor PJ, and Meldrum C
- Subjects
- ADAMTS13 Protein, Age of Onset, Arthritis, Rheumatoid complications, Female, Humans, Middle Aged, Mutation, Missense, Purpura, Thrombotic Thrombocytopenic complications, Purpura, Thrombotic Thrombocytopenic genetics, ADAM Proteins genetics, Purpura, Thrombotic Thrombocytopenic diagnosis
- Published
- 2015
- Full Text
- View/download PDF
136. Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury.
- Author
-
Nguyen TC, Cruz MA, and Carcillo JA
- Subjects
- ADAM Proteins blood, ADAM Proteins genetics, ADAMTS13 Protein, Acute Kidney Injury metabolism, Antibodies, Monoclonal, Humanized therapeutic use, Complement Inactivating Agents therapeutic use, Complement System Proteins metabolism, Disseminated Intravascular Coagulation metabolism, Disseminated Intravascular Coagulation therapy, Hemolytic-Uremic Syndrome genetics, Hemolytic-Uremic Syndrome microbiology, Hemolytic-Uremic Syndrome therapy, Humans, Multiple Organ Failure metabolism, Multiple Organ Failure therapy, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic metabolism, Purpura, Thrombotic Thrombocytopenic therapy, Shiga Toxins metabolism, Thromboplastin metabolism, von Willebrand Factor genetics, von Willebrand Factor metabolism, Acute Kidney Injury etiology, Disseminated Intravascular Coagulation complications, Hemolytic-Uremic Syndrome complications, Multiple Organ Failure etiology, Purpura, Thrombotic Thrombocytopenic complications
- Abstract
Thrombocytopenia-associated multiple organ failure (TAMOF) is a clinical phenotype that encompasses a spectrum of syndromes associated with disseminated microvascular thromboses, such as the thrombotic microangiopathies thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) and disseminated intravascular coagulation (DIC). Autopsies findings in TTP, HUS, or DIC reveal specific findings that can differentiate these 3 entities. Von Willebrand factor and ADAMTS-13 play a central role in TTP. Shiga toxins and the complement pathway are vital in the development of HUS. Tissue factor is the major protease that drives the pathology of DIC. Acute kidney injury (AKI) is a common feature in patients with TAMOF., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
137. Adult-onset congenital thrombotic thrombocytopenic purpura caused by a novel compound heterozygous mutation of the ADAMTS13 gene.
- Author
-
Krabbe JG, Kemna EW, Strunk AL, Jobse PA, Kramer PA, Dikkeschei LD, van den Heuvel LP, Fijnheer R, and Verdonck LF
- Subjects
- ADAMTS13 Protein, Age of Onset, Amino Acid Substitution, Humans, Male, Middle Aged, ADAM Proteins genetics, Exons, Heterozygote, Mutation, Missense, Purpura, Thrombotic Thrombocytopenic genetics
- Abstract
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease, characterized by microangiopathic hemolytic anaemia and thrombocytopenia, resulting in neurologic and/or renal abnormalities. We report a 49-year-old patient with a history of thrombotic events, renal failure, and thrombocytopenia. Blood analysis demonstrated no ADAMTS13 activity in the absence of antibodies against ADAMTS13. The complete ADAMTS13 gene was sequenced, and two mutations were identified: one mutation on exon 24 (Arg1060Asp), which had previously been described, and a mutation on exon 27 (Met1260IlefsX34), which has not been reported. For these mutations, compound heterozygosity appears to be necessary to cause TTP, as family members of the patient display only one of the mutations and all displayed normal ADAMTS13 activity.
- Published
- 2015
- Full Text
- View/download PDF
138. Upshaw-Schulman Syndrome.
- Author
-
Ahmad R, Natiq M, and Aziz M
- Subjects
- Adolescent, Female, Humans, Plasmapheresis, Purpura, Thrombotic Thrombocytopenic genetics, Treatment Outcome, Plasma, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic therapy
- Abstract
A13 years girl presented with history of sudden onset fits, altered sensorium and anuria for 2 days. There was also history of right sided weakness of the whole body. Past history revealed repeated episodes of similar complaints since early childhood. On the basis of history, physical examination and extensive investigations, patient was diagnosed as Upshaw-Schulman syndrome, a rare case of congenital Thrombotic Thrombocytopenic Purpura (TTP). She is now in remission and being maintained on twice weekly transfusions of Fresh Frozen Plasma (FFP).
- Published
- 2015
- Full Text
- View/download PDF
139. Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura.
- Author
-
Han B, Page EE, Stewart LM, Deford CC, Scott JG, Schwartz LH, Perdue JJ, Terrell DR, Vesely SK, and George JN
- Subjects
- ADAM Proteins genetics, ADAMTS13 Protein, Adult, Aged, Cognition Disorders etiology, Cognition Disorders genetics, Cognition Disorders therapy, Convalescence, Depression etiology, Depression genetics, Depression therapy, Depressive Disorder, Major etiology, Depressive Disorder, Major genetics, Depressive Disorder, Major therapy, Female, Gene Expression, Humans, Intelligence Tests, Male, Middle Aged, Neuropsychological Tests, Plasma Exchange, Purpura, Thrombotic Thrombocytopenic complications, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic therapy, Severity of Illness Index, Cognition Disorders psychology, Depression psychology, Depressive Disorder, Major psychology, Purpura, Thrombotic Thrombocytopenic psychology, Registries
- Abstract
After recovery from an acute episode of acquired thrombotic thrombocytopenic purpura (TTP), patients often describe problems with memory, concentration, and endurance. We have previously reported the occurrence of depression and cognitive impairment in these patients. In this study, we describe the frequency, severity, and clinical course of depression and cognitive impairment. Fifty-two (85%) out of 61 eligible Oklahoma Registry patients who had recovered from TTP, documented by ADAMTS13 activity <10%, have had at least one (median, four) evaluation for depression over 11 years using the Beck Depression Inventory-II; 31 (59%) patients screened positive for depression at least once; in 15 (29%), the results suggested severe depression at least once. Nine of these 15 patients had a psychiatric interview, the definitive diagnostic evaluation; the diagnosis of major depressive disorder was established in eight (89%) patients. In 2014, cognitive ability was evaluated in 33 patients by the Montreal Cognitive Assessment and the Repeatable Battery for Assessment of Neuropsychological Status (RBANS). Both tests detected significant cognitive impairment in the patients as a group. Fifteen out of the 33 patients had been evaluated by extensive cognitive tests in 2006. The 2014 RBANS results were significantly worse than the 2006 results for the overall score and two out of the five RBANS domains (immediate and delayed memory). Neither depression nor cognitive impairment was significantly associated with the occurrence of relapses or ADAMTS13 activity <10% during remission. These observations emphasize the importance of screening evaluations for depression and cognitive impairment after recovery from acquired TTP., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
140. Congenital and acquired ADAMTS13 deficiency: Two mechanisms, one patient.
- Author
-
Ferrari B, Cairo A, Pontiggia S, Mancini I, Masini L, and Peyvandi F
- Subjects
- ADAM Proteins blood, ADAMTS13 Protein, Adult, Autoantibodies chemistry, Environmental Exposure, Family Health, Female, Humans, Infant, Newborn, Male, Mutation, Missense, Pedigree, Phenotype, Point Mutation, Purpura, Thrombotic Thrombocytopenic blood, Purpura, Thrombotic Thrombocytopenic congenital, Ticlopidine chemistry, ADAM Proteins deficiency, ADAM Proteins genetics, Purpura, Thrombotic Thrombocytopenic genetics
- Abstract
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening microangiopathy with a heterogeneous and largely unpredictable course. It is caused by ADAMTS13 deficiency, that can be either congenital or due to anti-ADAMTS13 autoantibodies development. ADAMTS13 deficiency is necessary but not always sufficient to cause acute clinical manifestations and trigger factors may be needed. We report the case of a woman diagnosed with congenital TTP in her adulthood, presenting with anti-ADAMTS13 autoantibodies in acute phase during ticlopidine consumption. Noteworthy, the two ADAMTS13 mutations identified in this patient are novel: one is a splice-site mutation located in intron 11 (c.1308+2_5delTAGG) and the other is a point missense mutation in exon 29 (c.4184T>C leading to p.Leu1395Pro substitution). Since congenital TTP is an extremely rare disease and drug-induced TTP is an uncommon side effect of treatment with ticlopidine, the simultaneous occurrence of both mechanisms of disease in one patient is exceptional. This case represents TTP as a multifactorial disease, with ADAMTS13 genetic abnormality and environmental exposures acting together in determining individual clinical phenotype., (© 2014 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
141. Modified Ham test for atypical hemolytic uremic syndrome.
- Author
-
Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS, Moliterno AR, Sperati CJ, and Brodsky RA
- Subjects
- Adult, Aged, Atypical Hemolytic Uremic Syndrome genetics, Cell Survival, Female, Humans, Male, Membrane Proteins blood, Membrane Proteins genetics, Middle Aged, Purpura, Thrombotic Thrombocytopenic blood, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic genetics, Serum metabolism, Atypical Hemolytic Uremic Syndrome blood, Atypical Hemolytic Uremic Syndrome diagnosis
- Abstract
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by excessive activation of the alternative pathway of complement (APC). Atypical HUS is frequently a diagnosis of exclusion. Differentiating aHUS from other TMAs, especially thrombotic thrombocytopenic purpura (TTP), is difficult due to overlapping clinical manifestations. We sought to develop a novel assay to distinguish aHUS from other TMAs based on the hypothesis that paroxysmal nocturnal hemoglobinuria cells are more sensitive to APC-activated serum due to deficiency of glycosylphosphatidylinositol- anchored complement regulatory proteins (GPI-AP). Here, we demonstrate that phosphatidylinositol-specific phospholipase C-treated EA.hy926 cells and PIGA-mutant TF-1 cells are more susceptible to serum from aHUS patients than parental EA.hy926 and TF-1 cells. We next studied 31 samples from 25 patients with TMAs, including 9 with aHUS and 12 with TTP. Increased C5b-9 deposition was evident by confocal microscopy and flow cytometry on GPI-AP-deficient cells incubated with aHUS serum compared with heat-inactivated control, TTP, and normal serum. Differences in cell viability were observed in biochemically GPI-AP-deficient cells and were further increased in PIGA-deficient cells. Serum from patients with aHUS resulted in a significant increase of nonviable PIGA-deficient TF-1 cells compared with serum from healthy controls (P < .001) and other TMAs (P < .001). The cell viability assay showed high reproducibility, sensitivity, and specificity in detecting aHUS. In conclusion, we developed a simple, rapid, and serum-based assay that helps to differentiate aHUS from other TMAs., (© 2015 by The American Society of Hematology.)
- Published
- 2015
- Full Text
- View/download PDF
142. [The Cutting-edge of Medicine: Pathophysiology and Management of thrombotic thrombocytopenic purpura].
- Author
-
Yagi H and Matsumoto M
- Subjects
- ADAM Proteins genetics, ADAMTS13 Protein, Humans, Plasma Exchange, Platelet Aggregation, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic physiopathology, Recurrence, von Willebrand Factor metabolism, Purpura, Thrombotic Thrombocytopenic therapy
- Published
- 2015
- Full Text
- View/download PDF
143. A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity.
- Author
-
Rossio R, Lotta LA, Pontiggia S, Borsa NG, Garagiola I, Ardissino G, Mikovic D, Cugno M, and Peyvandi F
- Subjects
- ADAM Proteins immunology, ADAMTS13 Protein, Adult, Atypical Hemolytic Uremic Syndrome genetics, Atypical Hemolytic Uremic Syndrome immunology, Base Sequence, Child, Complement Pathway, Alternative genetics, Complement Pathway, Classical genetics, Diagnosis, Differential, Female, Gene Expression, Heterozygote, Humans, Male, Membrane Cofactor Protein immunology, Molecular Sequence Data, Mutation, Pedigree, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic immunology, von Willebrand Factor genetics, von Willebrand Factor immunology, ADAM Proteins genetics, Atypical Hemolytic Uremic Syndrome diagnosis, Membrane Cofactor Protein genetics
- Published
- 2015
- Full Text
- View/download PDF
144. Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura.
- Author
-
Edgar CE, Terrell DR, Vesely SK, Wren JD, Dozmorov IM, Niewold TB, Brown M, Zhou F, Frank MB, Merrill JT, Kremer Hovinga JA, Lämmle B, James JA, George JN, and Farris AD
- Subjects
- ADAMTS13 Protein, Adult, Autoantibodies immunology, Female, Gene Expression Regulation, Humans, Interferon Type I metabolism, Killer Cells, Natural immunology, Male, Middle Aged, Phenotype, Purpura, Thrombotic Thrombocytopenic pathology, RNA, Messenger genetics, RNA, Messenger metabolism, Recurrence, T-Lymphocytes immunology, ADAM Proteins deficiency, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic immunology, Ribosomes metabolism
- Abstract
Approximately 40% of patients who survive acute episodes of thrombotic thrombocytopenic purpura (TTP) associated with severe acquired ADAMTS13 deficiency experience one or more relapses. Risk factors for relapse other than severe ADAMTS13 deficiency and ADAMTS13 autoantibodies are unknown. ADAMTS13 autoantibodies, TTP episodes following infection or type I interferon treatment and reported ensuing systemic lupus erythematosus in some patients suggest immune dysregulation. This cross-sectional study asked whether autoantibodies against RNA-binding proteins or peripheral blood gene expression profiles measured during remission are associated with history of prior relapse in acquired ADAMTS13-deficient TTP. Peripheral blood from 38 well-characterized patients with autoimmune ADAMTS13-deficient TTP in remission was examined for autoantibodies and global gene expression. A subset of TTP patients (9 patients, 24%) exhibited a peripheral blood gene signature composed of elevated ribosomal transcripts that associated with prior relapse. A non-overlapping subset of TTP patients (9 patients, 24%) displayed a peripheral blood type I interferon gene signature that associated with autoantibodies to RNA-binding proteins but not with history of relapse. Patients who had relapsed bimodally expressed higher HLA transcript levels independently of ribosomal transcripts. Presence of any one potential risk factor (ribosomal gene signature, elevated HLA-DRB1, elevated HLA-DRB5) associated with relapse (OR = 38.4; p = 0.0002) more closely than any factor alone or all factors together. Levels of immune transcripts typical of natural killer (NK) and T lymphocytes positively correlated with ribosomal gene expression and number of prior episodes but not with time since the most recent episode. Flow cytometry confirmed elevated expression of cell surface markers encoded by these transcripts on T and/or NK cell subsets of patients who had relapsed. These data associate elevated ribosomal and immune transcripts with relapse history in acquired, ADAMTS13-deficient TTP.
- Published
- 2015
- Full Text
- View/download PDF
145. The novel ADAMTS13-p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice.
- Author
-
De Cock E, Hermans C, De Raeymaecker J, De Ceunynck K, De Maeyer B, Vandeputte N, Vandenbulcke A, Deckmyn H, Rottensteiner H, De Maeyer M, De Meyer SF, and Vanhoorelbeke K
- Subjects
- ADAM Proteins blood, ADAM Proteins deficiency, ADAMTS13 Protein, Adult, Animals, Binding Sites, Calcium blood, DNA Mutational Analysis, Disease Models, Animal, Female, Genetic Predisposition to Disease, HEK293 Cells, Homozygote, Humans, Metalloendopeptidases deficiency, Mice, Knockout, Molecular Dynamics Simulation, Phenotype, Pregnancy, Protein Binding, Purpura, Thrombotic Thrombocytopenic blood, Purpura, Thrombotic Thrombocytopenic enzymology, Transfection, ADAM Proteins genetics, Blood Platelets enzymology, Metalloendopeptidases genetics, Mutation, Missense, Purpura, Thrombotic Thrombocytopenic genetics
- Abstract
Background: Congenital thrombotic thrombocytopenic purpura (TTP) is characterized by mutations in the ADAMTS13 gene, which either impair protein secretion or influence ADAMTS13 (A Disintegrin-like And Metalloprotease domain with ThromboSpondin type-1 motif, member 13) activity. Phenotypic consequences of these mutations have not yet been evaluated in animal models for TTP., Objectives: To identify the in vitro effect of a novel ADAMTS13 mutation and to investigate whether this mutation induces TTP in vivo., Methods: All 29 ADAMTS13 exons with exon-intron boundaries of a patient with pregnancy-onset TTP were sequenced. Wild-type and mutant ADAMTS13 proteins were both transiently and stably expressed in human embryonic kidney cells, and their activity was evaluated in vitro using fluorescence resonance energy transfer and flow assays. Molecular dynamics simulations were performed to study Ca(2+) stability. Adamts13(-/-) mice were hydrodynamically injected with wild-type and mutant expression plasmids and triggered with recombinant human von Willebrand factor., Results: We identified a novel heterozygous c.559G>C mutation in exon 6 of the proposita's ADAMTS13 gene. This mutation resulted in a p.Asp187His substitution (p.D187H), which was located in the high affinity Ca(2+) -binding site in the metalloprotease domain of ADAMTS13. The homozygous p.D187H mutation down-regulated ADAMTS13 activity in vitro. Impaired proteolytic activity was linked to unstable Ca(2+) binding as visualized using a molecular dynamics simulation. In addition, the p.D187H mutation affects protein secretion in vitro. In Adamts13(-/-) mice, the homozygous p.D187H mutation reduced ADAMTS13 secretion and activity and contributed to TTP when these mice were triggered with recombinant human von Willebrand factor., Conclusions: Our data indicate that the p.D187H mutation impairs ADAMTS13 activity and secretion and is responsible for TTP onset in mice., (© 2014 International Society on Thrombosis and Haemostasis.)
- Published
- 2015
- Full Text
- View/download PDF
146. [Atypical HUS caused by complement-related abnormalities].
- Author
-
Yoshida Y and Matsumoto M
- Subjects
- Animals, Atypical Hemolytic Uremic Syndrome genetics, Atypical Hemolytic Uremic Syndrome immunology, Humans, Immunologic Deficiency Syndromes genetics, Mutation genetics, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic immunology, Atypical Hemolytic Uremic Syndrome diagnosis, Complement System Proteins metabolism, Early Diagnosis, Immunologic Deficiency Syndromes diagnosis, Purpura, Thrombotic Thrombocytopenic diagnosis
- Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. The term aHUS was historically used to distinguish this disorder from Shiga-toxin producing Escherichia coli (STEC)-HUS. Many aHUS cases (approximately 70%) are reportedly caused by uncontrolled complement activation due to genetic mutations in the alternative pathway, including complement factor H (CFH), complement factor I (CFI), membrane cofactor protein (MCP), thrombomodulin (THBD), complement component C3 (C3), and complement factor B (CFB). Mutations in the coagulation pathway, such as diacylglycerol kinase ε (DGKE) and plasminogen, are also reported to be causes of aHUS. In this review, we have focused on aHUS due to complement dysfunction. aHUS is suspected based on plasma ADAMTS13 activity of 10% or more, and being negative for STEC-HUS, in addition to the aforementioned triad. Complement genetic studies provide a more specific diagnosis of aHUS. Plasma therapy is the first-line treatment for patients with aHUS and should be initiated as soon as the diagnosis is suspected. Recently, eculizumab, a humanized monoclonal antibody against C5, was shown to be an effective treatment for aHUS. Therefore, early diagnosis and identification of the underlying pathogenic mechanism is important for improving the outcome of aHUS.
- Published
- 2015
- Full Text
- View/download PDF
147. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center.
- Author
-
Benhamou Y, Boelle PY, Baudin B, Ederhy S, Gras J, Galicier L, Azoulay E, Provôt F, Maury E, Pène F, Mira JP, Wynckel A, Presne C, Poullin P, Halimi JM, Delmas Y, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Hamidou M, Cohen A, Veyradier A, and Coppo P
- Subjects
- ADAM Proteins deficiency, ADAM Proteins genetics, ADAMTS13 Protein, Adult, Aged, Biomarkers blood, Chi-Square Distribution, Electrocardiography, Female, France, Heart Diseases diagnosis, Heart Diseases mortality, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Predictive Value of Tests, Prognosis, Prospective Studies, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic mortality, Registries, Risk Factors, Time Factors, Up-Regulation, Heart Diseases blood, Heart Diseases etiology, Purpura, Thrombotic Thrombocytopenic blood, Purpura, Thrombotic Thrombocytopenic complications, Troponin I blood
- Abstract
Background: Cardiac involvement is a major cause of mortality in patients with thrombotic thrombocytopenic purpura (TTP). However, diagnosis remains underestimated and delayed, owing to subclinical injuries. Cardiac troponin-I measurement (cTnI) on admission could improve the early diagnosis of cardiac involvement and have prognostic value., Objectives: To assess the predictive value of cTnI in patients with TTP for death or refractoriness., Patients/methods: The study involved a prospective cohort of adult TTP patients with acquired severe ADAMTS-13 deficiency (< 10%) and included in the registry of the French Reference Center for Thrombotic Microangiopathies. Centralized cTnI measurements were performed on frozen serum on admission., Results: Between January 2003 and December 2011, 133 patients with TTP (mean age, 48 ± 17 years) had available cTnI measurements on admission. Thirty-two patients (24%) had clinical and/or electrocardiogram features. Nineteen (14.3%) had cardiac symptoms, mainly congestive heart failure and myocardial infarction. Electrocardiogram changes, mainly repolarization disorders, were present in 13 cases. An increased cTnI level (> 0.1 μg L(-1) ) was present in 78 patients (59%), of whom 46 (59%) had no clinical cardiac involvement. The main outcomes were death (25%) and refractoriness (17%). Age (P = 0.02) and cTnI level (P = 0.002) showed the greatest impact on survival. A cTnI level of > 0.25 μg L(-1) was the only independent factor in predicting death (odds ratio [OR] 2.87; 95% confidence interval [CI] 1.13-7.22; P = 0.024) and/or refractoriness (OR 3.03; 95% CI 1.27-7.3; P = 0.01)., Conclusions: A CTnI level of > 0.25 μg L(-1) at presentation in patients with TTP appears to be an independent factor associated with a three-fold increase in the risk of death or refractoriness. Therefore, cTnI level should be considered as a prognostic indicator in patients diagnosed with TTP., (© 2014 International Society on Thrombosis and Haemostasis.)
- Published
- 2015
- Full Text
- View/download PDF
148. Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy.
- Author
-
von Auer C, von Krogh AS, Kremer Hovinga JA, and Lämmle B
- Subjects
- ADAMTS13 Protein, Causality, Comorbidity, Female, Genetic Predisposition to Disease genetics, Humans, Incidence, Mutation genetics, Polymorphism, Single Nucleotide genetics, Pregnancy, Risk Factors, Survival Rate, ADAM Proteins genetics, Pregnancy Complications, Cardiovascular genetics, Pregnancy Complications, Cardiovascular mortality, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic mortality
- Abstract
The complex relation between thrombotic thrombocytopenic purpura (TTP) and pregnancy is concisely reviewed. Pregnancy is a very strong trigger for acute disease manifestation in patients with hereditary TTP caused by double heterozygous or homozygous mutations of ADAMTS13 (ADisintegrin And Metalloprotease with ThromboSpondin type 1 domains, no. 13). In several affected women disease onset during their first pregnancy leads to the diagnosis of hereditary TTP. Without plasma treatment mother and especially fetus are at high risk of dying. The relapse risk during a next pregnancy is almost 100% but regular plasma transfusion starting in early pregnancy will prevent acute TTP flare-up and may result in successful pregnancy outcome. Pregnancy may also constitute a mild risk factor for the onset of acute acquired TTP caused by autoantibody-mediated severe ADAMTS13 deficiency. Women having survived acute acquired TTP may not be at very high risk of TTP relapse during an ensuing next pregnancy but seem to have an elevated risk of preeclampsia. Monitoring of ADAMTS13 activity and inhibitor titre during pregnancy may help to guide management and to avoid disease recurrence. Finally, TTP needs to be distinguished from the much more frequent hypertensive pregnancy complications, preeclampsia and especially HELLP (Hemolysis, Elevated Liver Enzymes, Low Platelet count) syndrome., (© 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
149. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
- Author
-
Zheng XL
- Subjects
- ADAM Proteins immunology, ADAMTS13 Protein, Autoantibodies immunology, Genetic Therapy methods, Humans, Mutation, Purpura, Thrombotic Thrombocytopenic immunology, Purpura, Thrombotic Thrombocytopenic therapy, Recombinant Proteins therapeutic use, ADAM Proteins genetics, Purpura, Thrombotic Thrombocytopenic genetics, von Willebrand Factor metabolism
- Abstract
Pathogenesis of thrombotic thrombocytopenic purpura (TTP) was a mystery for over half a century until the discovery of ADAMTS13. ADAMTS13 is primarily synthesized in the liver, and its main function is to cleave von Willebrand factor (VWF) anchored on the endothelial surface, in circulation, and at the sites of vascular injury. Deficiency of plasma ADAMTS13 activity (<10%) resulting from mutations of the ADAMTS13 gene or autoantibodies against ADAMTS13 causes hereditary or acquired (idiopathic) TTP. ADAMTS13 activity is usually normal or modestly reduced (>20%) in other forms of thrombotic microangiopathy secondary to hematopoietic progenitor cell transplantation, infection, and disseminated malignancy or in hemolytic uremic syndrome. Plasma infusion or exchange remains the initial treatment of choice to date, but novel therapeutics such as recombinant ADAMTS13 and gene therapy are under development. Moreover, ADAMTS13 deficiency has been shown to be a risk factor for the development of myocardial infarction, stroke, cerebral malaria, and preeclampsia.
- Published
- 2015
- Full Text
- View/download PDF
150. Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura.
- Author
-
Raval JS, Padmanabhan A, Kremer Hovinga JA, and Kiss JE
- Subjects
- ADAM Proteins genetics, ADAMTS13 Protein, Adult, Female, Humans, Mutation, Treatment Outcome, ADAM Proteins antagonists & inhibitors, Plasma Exchange adverse effects, Purpura, Thrombotic Thrombocytopenic enzymology, Purpura, Thrombotic Thrombocytopenic genetics, Purpura, Thrombotic Thrombocytopenic therapy
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.